tiprankstipranks
Trending News
More News >
Hoth Therapeutics Inc (HOTH)
NASDAQ:HOTH
US Market
Advertisement

Hoth Therapeutics (HOTH) Price & Analysis

Compare
430 Followers

HOTH Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Clinical TrialsThe open-label portion of HT-001 trial yields promising results, with 100% of patients achieving the primary efficacy endpoint, showing significant skin toxicity improvement.
Market OpportunitiesThe obesity market represents a large commercial opportunity, with favorable early results potentially constituting a substantial value inflection point.
PartnershipsThe company has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs, providing rights to a groundbreaking innovation aimed at treating obesity and associated health conditions.
Bears Say
Intellectual PropertyAdvancements in intellectual property may provide the ability to secure market exclusivity for additional indications addressable with HT-001, Hoth's most advanced asset.

Hoth Therapeutics News

HOTH FAQ

What was Hoth Therapeutics Inc’s price range in the past 12 months?
Hoth Therapeutics Inc lowest stock price was $0.58 and its highest was $3.80 in the past 12 months.
    What is Hoth Therapeutics Inc’s market cap?
    Hoth Therapeutics Inc’s market cap is $17.24M.
      When is Hoth Therapeutics Inc’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Hoth Therapeutics Inc’s earnings last quarter?
      Currently, no data Available
      Is Hoth Therapeutics Inc overvalued?
      According to Wall Street analysts Hoth Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Hoth Therapeutics Inc pay dividends?
        Hoth Therapeutics Inc does not currently pay dividends.
        What is Hoth Therapeutics Inc’s EPS estimate?
        Hoth Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Hoth Therapeutics Inc have?
        Hoth Therapeutics Inc has 13,208,915 shares outstanding.
          What happened to Hoth Therapeutics Inc’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Hoth Therapeutics Inc?
          Currently, no hedge funds are holding shares in HOTH

          Company Description

          Hoth Therapeutics Inc

          Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

          Hoth Therapeutics (HOTH) Earnings & Revenues

          Currently, no data available
          Please return soon. This page is being updated.
          Similar Stocks
          Company
          Price & Change
          Follow
          Bioline RX Ltd Sponsored ADR
          NextCure
          Capstone Therapeutics
          Sensei Biotherapeutics
          Rallybio

          Ownership Overview

          0.53%0.99%0.42%97.78%
          0.42% Other Institutional Investors
          97.78% Public Companies and Individual Investors

          Options Prices

          Currently, No data available
          ---
          Popular Stocks
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis